Due to high GC content of the TERT promoter, and this being a chronologically later mutational hit, we believe BRAF p.V600 and NRAS p.Q61/p.G12 variants to be the best pharmacodynamic biomarkers to monitor treatment response in mutation positive malignant melanoma patients. This evidence concerns the gene BRAF and melanoma.